Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival

Marietta Nygaard, Niels Smedegaard Andersen, Claus Ernst Moser, Gitte Olesen, Ida Marie Schjødt, Carsten Heilmann, Henrik Sengeløv

5 Citationer (Scopus)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Evaluation of infliximab as second-line treatment of acute graft versus host disease -validating response on day 7 and 28 as predictors of survival'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab